Treatment Archives | VJDementia

FDA approves lecanemab for the treatment of Alzheimer’s disease

On January 6, 2023, the US Food and Drug Administration (FDA) approved lecanemab for the treatment of Alzheimer’s disease (AD),…

Phase III EXERT trial: exercise shown to stall cognitive decline in patients with mild cognitive impairment

The Phase III, multicenter, randomized EXERT trial enrolled almost 300 patients to investigate the effects of regular exercise on brain…

Highlights from ARUK 2022

The Alzheimer’s Research UK Conference was held in Brighton, UK, on 1-2 March 2022. Leading experts discussed the key topics…

Nasal vaccine for Alzheimer’s disease enters first-in-human trial

In recent years, there has been a greater interest in gaining further insight into the relationship between Alzheimer’s disease (AD)…

The Phase II/III GAIN Trial: atuzaginstat for mild-moderate Alzheimer’s disease

Atuzaginstat, a novel small-molecule bacterial protease lysine gingipain inhibitor, is currently under investigation as a first-in-class treatment to slow or…

Novel antibody donanemab receives FDA breakthrough designation for Alzheimer’s disease

A hallmark feature of Alzheimer’s disease (AD) is the aggregation of amyloid-β (Aβ). Although many trials have been conducted aiming…

Aducanumab receives accelerated FDA approval for early Alzheimer’s disease

The Food and Drug Administration (FDA) has granted accelerated approval to aducanumab for the treatment of early Alzheimer’s disease (AD)….

features: Treatment